Phase III randomized trial of sunitinib malate (SU1 1248) versus interferon-alfa (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) Meeting Abstract


Authors: Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Kim, S. T.; Baum, C. M.; Figlin, R. A.
Abstract Title: Phase III randomized trial of sunitinib malate (SU1 1248) versus interferon-alfa (IFN-alpha) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)
Meeting Title: 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 24
Issue: 18 Suppl. Pt. 1
Meeting Dates: 2006 Jun 2-6
Meeting Location: Atlanta, GA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2006-06-01
Start Page: 2S
Language: English
ACCESSION: WOS:000239009400004
PROVIDER: wos
DOI: 10.1200/jco.2006.24.18_suppl.lba3
Notes: --- - Meeting Abstract: LBA3 - 42nd Annual Meeting of the American-Society-of-Clinical-Oncology - JUN 02-06, 2006 - Atlanta, GA - S - Part 1 - "Source: Wos"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer